• Document download center

    Here you will find all the product information, technical and support documents relating to our protein biomarker panels. Most of these documents apply to our current product portfolio only, but the Data Validation documents for our discontinued panels are also available below.

    Please note: it is not recommended to give links directly to the pdf files on this page (for example, as a reference link in a publication), because any subsequent updates to the files will change the timestamp information in the URL and break the original link. Instead, we recommend referring to the document by name, and providing the page link, www.olink.com/downloads

  • Validation Data documents

    Here you can access full validation data information for both current and discontinued Olink panels. Please note that the content of some panels may have been updated over time. The documents below refer to the most recently available version of the panel only. If you need a previous version of one of our validation data documents that refers to an older version of the panel, please contact us directly.

    • CARDIOMETABOLIC

      panel uses a 1:2025 dilution of sample. The measuring ranges shown in Figure 3 correspond to the concentrations in the original biological sample, whereas the figures quoted in Table 1 represent the actual concentration of recombinant analyte measurable in the validation assay. A multiplication factor of 2025 should therefore be taken into consideration when comparing the addressable biological concentration to the in vitro validation data.

    • CELL REGULATION
    • CARDIOVASCULAR II
    • CARDIOVASCULAR III

      Note: the CVD III panel uses a 1:100 dilution of sample. The measuring ranges shown in Figure 3 correspond to the concentrations in the original biological sample, whereas the figures quoted in Table 1 represent the actual concentration of recombinant analyte measurable in the validation assay. A multiplication factor of 100 should therefore be taken into consideration when comparing the addressable biological concentration to the in vitro validation data.

    • DEVELOPMENT

      panel uses a 1:100 dilution of sample. The measuring ranges shown in Figure 3 correspond to the concentrations in the original biological sample, whereas the figures quoted in Table 1 represent the actual concentration of recombinant analyte measurable in the validation assay. A multiplication factor of 100 should therefore be taken into consideration when comparing the addressable biological concentration to the in vitro validation data.

    • IMMUNE RESPONSE
    • IMMUNO-ONCOLOGY

      Note that this version (2.1) applies to the latest panel version with article number 95311

    • INFLAMMATION

      Note that this version (3.0) applies to the latest panel version with article number 95302

    • METABOLISM

      Note: the Metabolism panel uses a 1:10 dilution of sample. The measuring ranges shown in Figure 3 correspond to the concentrations in the original biological sample, whereas the figures quoted in Table 1 represent the actual concentration of recombinant analyte measurable in the validation assay. A multiplication factor of 10 should therefore be taken into consideration when comparing the addressable biological concentration to the in vitro validation data.

    • MOUSE EXPLORATORY
    • NEUROLOGY
    • NEURO EXPLORATORY
    • ONCOLOGY II
    • ONCOLOGY III
    • ORGAN DAMAGE
    • CVD I (discontinued)
    • ONCOLOGY I, v2 (discontinued)

  • Biomarker lists

    Here you can access the complete biomarker assay list for each panel, listing the long name, short name and UniProt number for each protein. Since an individual protein may have a number of commonly used names or abbreviations, we recommend using the UniProt ID provided to search the UniProt website if there is any uncertainty.

    To view all of the biomarker assays available in our current portfolio, please go to our Complete Biomarker List page, where you can also link directly to the individual biomarker pages that display the relevant validation data.

    Please note that the content of some panels may have been updated over time. The documents below refer to the most recently available version of the panel only. If you need a previous version of one of our Biomarker list documents that refers to an older version of the panel, please contact us directly.

    • CARDIOMETABOLIC
    • CELL REGULATION
    • CARDIOVASCULAR II
    • CARDIOVASCULAR III
    • DEVELOPMENT
    • IMMUNE RESPONSE
    • IMMUNO-ONCOLOGY

      Note that this version (1.2) applies to the latest panel version with article number 95311

    • INFLAMMATION

      Note that this version (1.3) applies to the latest panel version with article number 95302

    • METABOLISM
    • NEUROLOGY
    • NEURO EXPLORATORY
    • ONCOLOGY II
    • ONCOLOGY III
    • ORGAN DAMAGE
    • MOUSE EXPLORATORY
    • CVD I (discontinued)

      Reference list for customers who have previously used this discontinued panel

    • ONCOLOGY I v2 (discontinued)

      Reference list for customers who have previously used this discontinued panel

  • White Papers

    Here you can find all the white papers that Olink have produced. These articles leverage the wealth of knowledge and experience in our research and development team, presenting you with useful technical and application-related information.

    • Measuring protein biomarkers with Olink — technical comparisons and orthogonal validation

      This white paper addresses how data from Olink studies compares to other technologies. We present examples of comparisons ranging from single-plex ELISAs to high multiplex assays and also provide useful tips for comparisons between Olink data and data from other technologies.

    • Strategies for design of protein biomarker studies

      This white paper describes important aspects of study design to consider when planning your future research.

    • Data normalization and standardization

      This paper describes Olink's built-in QC system, NPX calculation and definition, and the different normalization methods we use.

    • Pre-analytical variation in protein biomarker research

      This paper provides some guidance on what to consider with respect to sample collection and handling when setting up a protein biomarker study.

    • PEA: An enabling technology for high-multiplex protein biomarker discovery

      A short overview of how the unique technology behind Olink's biomarker panels works and how it overcomes the problems normally associated with multiplexed immunoassays.

    • Development and validation of customized PEA biomarker panels with clinical utility

      This describes how PEA can be applied to the development and validation of lower-plex assays that could help to translate protein signatures from discovery to clinical utility. The article shows a proof-of-concept study to design a custom panel including assays for both high and low abundance proteins, and providing absolute quantification.

  • Application examples

    Here you will find documents showing examples of data generated using specific Olink panels, or in specific application areas of interest.

    • Olink Mouse Exploratory - Pilot Studies
    • Neurology Focus

      Overview of the value of Olink's panels in neurology research. Includes application examples.

  • Technical notes

    Here you can download our technical notes, which provide information on technical aspects of our panels

    • Extending Olink's Mouse Exploratory panel to studies in rats
    • PEA specificity

  • Brochure

    Here you can download our brochure, which presents a concise overview of  the Olink offering.

  • Manuals & instructions

    Below you will find all our technical user documentation, including manuals, short instructions and guidelines.

    • User Manual

      New version updated Feb 7, 2019

    • Short Instructions
    • Sample Dilution Guideline 1:10
    • Sample Dilution Guidelines 1:100
    • Sample Dilution Guideline 1:2025
    • NPX Manager User Manual

  • Material Safety Data Sheets (MSDS)

    Please view our safety information documents relating to the different components of the panel kits.